Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human Placental Derived Mesenchymal Stem Cell are a well-characterized population of adult stem cells. These adult stem cells have a broad therapeutic potential due to their capability to renew and differentiate into various lineages of mature cells that produce fat, cartilage, bone, tendon, and muscle when cultured under specific permissive conditions. These cells are expanded in a Mesenchymal Stem Cell Medium and then cryopreserved at passage 2. The human placental MSC express typical mesenchymal cell surface markers, such as CD105, CD73, and CD90 and are negative for hematopoietic markers including CD34, CD45, and endothelial cell marker CD31.

Human iPSC-Derived Neural Stem Cells are a homogeneous and multipotent population derived from control Human Induced Pluripotent Stem Cells.

Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.

Human iPSC-derived Brain Microvascular Endothelial Cells (iBMECs) from Ace Therapeutics are derived from integration-free induced pluripotent stem cell (iPSC) lines under a fully defined proprietary induction condition. iBMEC cells are compact cellular structures when plated as a monolayer in culture and express standard biomarkers such as ECadherin and ZO-1 using immunohistochemistry methods and transporter biomarkers such as ABCB1 (P-gp), ABCG2, ABCE1, HIF1A, CLDN5, GLUT1, LAT1, MCT1, TJP1, PDGFbeta, OCLN, SLC25A3, TFR1, and SLC25A5 using RT/qPCR methods. Each vial contains at least 1×10^6 cells per ml and is delivered frozen.

CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.

Human Cord Blood-CD34+ Hematopoietic Stem Cell from Ace Therapeutics are isolated using positive magnetic isolation of CD34 from cord blood. CD34+ cells are targeted using uniform, superparamagnetic polymer beads coated with a primary monoclonal antibody specific for the CD34 membrane antigen predominantly expressed on human hematopoietic progenitor cells and endothelial progenitor cells. The isolated cells are poured off into a new tube and are cryogenically preserved.

Human Embryonic Hematopoietic Stem Cells (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice. Cells are only guaranteed with the purchase of Ace Therapeutics‘s Media and Ace Therapeutics‘s Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human endothelial progenitor cells (EPCs) are circulating cells that exhibit a range of cell surface markers comparable to those found on vascular endothelial cells. They encompass primitive endothelial cells that possess enhanced angiogenic and vasculogenic characteristics. These primitive endothelial cells have the remarkable capacity to proliferate and undergo differentiation, ultimately maturing into functional endothelial cells. Human Endothelial Progenitor Cell from Ace Therapeutics can be expanded for up to 120 population doublings or 12 passages, providing ample material for experimentation. They express positive markers such as CD31, CD144, (VEGF)R2, CD146, CD73, CD105, and exhibit the uptake of acetylated low-density lipoprotein. Furthermore, AcceGen provides one million viable cells upon thawing of the frozen vial, which is shipped in dry ice to maintain cell integrity during transportation.

Human iPSC Line (Episomal, PBMC) from Ace Therapeutics was derived from human mesenchymal stromal cells (MSCs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using episomal plasmids.